AFT Pharmaceuticals affirms it is on track to break even within two years

Pattrick Smellie
Fri, 05 Aug 2016

By Pattrick Smellie Aug. 5 (BusinessDesk) - Drug developer AFT Pharmaceuticals still expects to break even in the 2018 or 2019 financial year, although it cannot be sure exactly when, founder and managing director Harley Atkinson told shareholders at the company's first annual meeting since dual-listing on the NZX and ASX last December. "FY18 still looks close," said  Atkinson. "We might make a small loss or we might break even next year." The company reported an $8.9 million loss, in line with its prospectus, for the year to March 31,...
BRIAN GAYNOR: Aluminium smelter reaches use by date
Brian Gaynor | Sat, 11 Jul 2020

The negative market reaction to Rio Tinto’s announcement that it was winding down the Tiwai Point aluminium smelter was overdone, particularly for investors with long-term perspectives. The smelter...

MARKET CLOSE: NZ shares fall as energy sector sell-off continues
Dan Brunskill | Fri, 10 Jul 2020

New Zealand shares fell as energy stocks declined for a second day following the announcement Rio Tinto’s New Zealand aluminium smelter will close. Chorus led the market lower on the risk of more r...

Metlifecare and EQT enter new $6 per share takeover agreement
Jenny Ruth | Fri, 10 Jul 2020

Metlifecare said it has entered into a new scheme of arrangement with Swedish company EQT to buy all its shares for $6 each, a dollar less than the earlier deal EQT had repudiated, but only four of th...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.

Sponsored: What’s next for the future of the office?

Think everyone is going to keep working from home? No so fast, says Milford Asset Management.